🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07301892
Recruiting Observational

Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis

NCT07301892 · tracked via the Priya Life Science China tracker
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase
Observational
Started
2025-10-01
Last updated
2025-12-24

Condition(s) studied

Rheumatoid Arthritis (RAOsteoporosisOsteoarthritisInterstitial Lung DiseaseThyroid DiseasesCardiovascular DiseasesPulmonary ComplicationsSjogren's SyndromeLiver DisordersRenal LesionsVasculitisAmyloidosisPeripheral NeuropathyThrombosisRA Complications

Investigational drug(s) / intervention(s)

Generative AI prediction report for RA complications

Generative AI prediction report for RA complications: Generative AI based on multiple large language models (LLMs) is used to predict potential complications and co-existing diseases in patients with rheumatoid arthritis using EHR data available at admission. Physicians use these AI predictions as additional information to adjust their diagnostic plans during differential diagnosis. The impact of this intervention on the final diagnoses at discharge will be measured. Before the prospective study, the adoptability of the generative AI prediction reports will be validated using EHR records from retrospective RA patients.

Study summary

Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients with an initial diagnosis of rheumatoid arthritis (RA). * All real-world RA inpatients admitted to our department. * Admission occurring within the real-world data study period. Exclusion Criteria: * Patients subsequently confirmed not to have RA during the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Guang'anmen Hospital of China Academy of Chinese Medical Sciences Beijing Beijing Municipality Recruiting

More Guang'anmen Hospital of China Academy of Chinese Medical Sciences trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07301892 on ClinicalTrials.gov ↗ ← All trials in China